WO2020190023A3 - 단일 클로날 줄기세포를 이용한 아토피 피부염 치료 방법 - Google Patents

단일 클로날 줄기세포를 이용한 아토피 피부염 치료 방법 Download PDF

Info

Publication number
WO2020190023A3
WO2020190023A3 PCT/KR2020/003694 KR2020003694W WO2020190023A3 WO 2020190023 A3 WO2020190023 A3 WO 2020190023A3 KR 2020003694 W KR2020003694 W KR 2020003694W WO 2020190023 A3 WO2020190023 A3 WO 2020190023A3
Authority
WO
WIPO (PCT)
Prior art keywords
stem cells
atopic dermatitis
monoclonal
patients
mesenchymal stem
Prior art date
Application number
PCT/KR2020/003694
Other languages
English (en)
French (fr)
Other versions
WO2020190023A9 (ko
WO2020190023A2 (ko
Inventor
송순욱
최광성
조윤경
김시나
정은경
Original Assignee
에스씨엠생명과학 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스씨엠생명과학 주식회사 filed Critical 에스씨엠생명과학 주식회사
Priority to JP2021556666A priority Critical patent/JP2022528033A/ja
Priority to EP20774251.1A priority patent/EP3943091A4/en
Priority to CN202080022930.0A priority patent/CN113614538A/zh
Priority to US17/440,488 priority patent/US20220160777A1/en
Publication of WO2020190023A2 publication Critical patent/WO2020190023A2/ko
Publication of WO2020190023A3 publication Critical patent/WO2020190023A3/ko
Publication of WO2020190023A9 publication Critical patent/WO2020190023A9/ko
Priority to JP2023151563A priority patent/JP2023179507A/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5428—IL-10
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5437—IL-13
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)

Abstract

본 발명은 단일 클로날 줄기세포를 투여하여 아토피 피부염을 예방 또는 치료하기 위한 방법 및 조성물에 관한 것이다. 또한 본 발명은 상기 방법 및 조성물을 적용하기 위하여 단일 클로날 줄기세포 투여에 적합한 아토피 피부염 환자를 선별하고, 이들의 예후를 예측하기 위한 조성물 및 방법에 관한 것이다. 본 발명의 개선된 줄기세포의 층분리 배양 및 증식 방법에 따르면, 단일 클로날 중간엽 줄기세포의 빠른 증식을 통해 단시간에 원하는 단일 클로날 중간엽 줄기세포의 대량 수득이 가능하다. 또한 이를 통해 수득되는 단일 클로날 중간엽 줄기세포를 아토피 피부염을 갖는 환자에 정해진 투여 주기, 용법, 용량으로 투여하여 환자의 아토피 증상을 효과적으로 개선할 수 있을 뿐만 아니라, 특히 본 치료에 적합한 환자군을 마커에 따라 확인하고 선별 투여함으로써 우수한 아토피 피부염 치료 효과를 달성할 수 있다.
PCT/KR2020/003694 2019-03-19 2020-03-18 단일 클로날 줄기세포를 이용한 아토피 피부염 치료 방법 WO2020190023A2 (ko)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2021556666A JP2022528033A (ja) 2019-03-19 2020-03-18 単一クローナル幹細胞を用いたアトピー皮膚炎の治療方法
EP20774251.1A EP3943091A4 (en) 2019-03-19 2020-03-18 METHOD FOR TREATING ATOPIC DERMATITIS USING MONOCLONAL STEM CELLS
CN202080022930.0A CN113614538A (zh) 2019-03-19 2020-03-18 利用单克隆干细胞的特应性皮炎的治疗方法
US17/440,488 US20220160777A1 (en) 2019-03-19 2020-03-18 Method for treating atopic dermatitis using monoclonal stem cells
JP2023151563A JP2023179507A (ja) 2019-03-19 2023-09-19 単一クローナル幹細胞を用いたアトピー皮膚炎の治療方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0030900 2019-03-19
KR20190030900 2019-03-19

Publications (3)

Publication Number Publication Date
WO2020190023A2 WO2020190023A2 (ko) 2020-09-24
WO2020190023A3 true WO2020190023A3 (ko) 2020-12-17
WO2020190023A9 WO2020190023A9 (ko) 2021-02-04

Family

ID=72521108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/003694 WO2020190023A2 (ko) 2019-03-19 2020-03-18 단일 클로날 줄기세포를 이용한 아토피 피부염 치료 방법

Country Status (6)

Country Link
US (1) US20220160777A1 (ko)
EP (1) EP3943091A4 (ko)
JP (2) JP2022528033A (ko)
KR (1) KR102341080B1 (ko)
CN (1) CN113614538A (ko)
WO (1) WO2020190023A2 (ko)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090065478A (ko) * 2004-03-22 2009-06-22 오시리스 쎄라퓨틱스, 인크. 중간엽 줄기 세포 및 그에 대한 용도
KR20130073794A (ko) * 2011-12-23 2013-07-03 (주)치아줄기세포뱅크 줄기세포 분비 단백질을 이용한 아토피 개선용 조성물
KR20140076198A (ko) * 2012-12-12 2014-06-20 서울대학교산학협력단 성체줄기세포 추출물을 유효성분으로 함유하는 피부염 예방 또는 치료용 약학적 조성물
KR20150065147A (ko) * 2013-11-29 2015-06-12 인하대학교 산학협력단 클로날 중간엽 줄기세포를 포함하는, 아토피성 피부염 예방 또는 치료용 약학적 조성물
KR20170127011A (ko) * 2015-03-16 2017-11-20 제넨테크, 인크. Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005121320A1 (ja) * 2004-06-10 2008-04-10 協和醗酵工業株式会社 幹細胞自己複製促進剤
KR20060075676A (ko) 2004-12-28 2006-07-04 현익근 비닐,고무,천막재료로 쥬부식 기둥과 지붕,벽,바닥을만들어 에이야를 주입시켜 야영하우스와 침실을 만드는 방법
EP1876244A4 (en) 2005-04-04 2009-09-23 Asubio Pharma Co Ltd METHOD FOR RELATIVELY RISK OF ATOCHIC DERMATITIS EXTRACTION WITH INDIVIDUAL NUCLEOTIDE POLYMORPHISM GENANALYSIS
WO2006138720A2 (en) * 2005-06-17 2006-12-28 Sun Uk Song Isolation of multi-lineage stem cells
KR102084974B1 (ko) * 2013-07-30 2020-03-06 코아스템(주) 인간 골수 유래 중간엽 줄기세포를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약제학적 조성물
WO2017171491A1 (ko) * 2016-03-31 2017-10-05 재단법인 아산사회복지재단 줄기세포 추출물을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물
KR101984227B1 (ko) * 2017-11-06 2019-06-25 에스씨엠생명과학 주식회사 줄기세포의 층분리 배양 및 증식 방법
EP3903793A4 (en) * 2019-01-16 2022-11-02 SCM Lifescience Co., Ltd. PHARMACEUTICAL COMPOSITION WITH CLONAL STEM CELLS FOR THE PREVENTION OR TREATMENT OF ATOPIC DERMATITIS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090065478A (ko) * 2004-03-22 2009-06-22 오시리스 쎄라퓨틱스, 인크. 중간엽 줄기 세포 및 그에 대한 용도
KR20130073794A (ko) * 2011-12-23 2013-07-03 (주)치아줄기세포뱅크 줄기세포 분비 단백질을 이용한 아토피 개선용 조성물
KR20140076198A (ko) * 2012-12-12 2014-06-20 서울대학교산학협력단 성체줄기세포 추출물을 유효성분으로 함유하는 피부염 예방 또는 치료용 약학적 조성물
KR20150065147A (ko) * 2013-11-29 2015-06-12 인하대학교 산학협력단 클로날 중간엽 줄기세포를 포함하는, 아토피성 피부염 예방 또는 치료용 약학적 조성물
KR20170127011A (ko) * 2015-03-16 2017-11-20 제넨테크, 인크. Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
K NA, H S YOO, Y X ZHANG, M-S CHOI, K LEE, T G YI, S U SONG, M-S JEON: "Bone marrow-derived clonal mesenchymal stem cells inhibit ovalbumin-induced atopic dermatitis", CELL DEATH & DISEASE, vol. 5, no. 7, 1 July 2014 (2014-07-01), pages e1345 - e1345, XP055725660, DOI: 10.1038/cddis.2014.299 *

Also Published As

Publication number Publication date
KR102341080B1 (ko) 2021-12-20
JP2022528033A (ja) 2022-06-08
CN113614538A (zh) 2021-11-05
WO2020190023A9 (ko) 2021-02-04
EP3943091A4 (en) 2022-12-07
US20220160777A1 (en) 2022-05-26
JP2023179507A (ja) 2023-12-19
KR20200111640A (ko) 2020-09-29
WO2020190023A2 (ko) 2020-09-24
EP3943091A2 (en) 2022-01-26

Similar Documents

Publication Publication Date Title
Brunelin et al. The efficacy and safety of low frequency repetitive transcranial magnetic stimulation for treatment-resistant depression: the results from a large multicenter French RCT
Midtgaard et al. Efficacy of multimodal exercise-based rehabilitation on physical activity, cardiorespiratory fitness, and patient-reported outcomes in cancer survivors: a randomized, controlled trial
BR112021018627A2 (pt) Combinação de inibidores da via de il-4/il-13 e ablação de células plasmáticas para o tratamento de alergia
Liu et al. Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation
WO2022150732A3 (en) Chimeric receptor therapy
RU2017107033A (ru) Способы лечения депрессии с применением модуляторов nmda
WO2020190023A3 (ko) 단일 클로날 줄기세포를 이용한 아토피 피부염 치료 방법
Shima et al. Discontinuation of tyrosine kinase inhibitor in children with chronic myeloid leukemia (JPLSG STKI-14 study)
Wang et al. Effects of irradiation with different fractionations on radioresistant esophageal cancer cells and lung tissues
Castro et al. Dupilumab efficacy in uncontrolled, moderate-to-severe allergic asthma in the phase 3 Liberty asthma quest study
Aggarwal et al. Neuroimmunomodulation by gut bacteria: Focus on inflammatory bowel diseases
Nemeroff Psychopharmacology and the future of personalized treatment
Moder et al. Effects of low-dose radon therapy applied under hyperthermic conditions (RnHT) on inflammatory and non-inflammatory degenerative disease conditions
Dalla Bella et al. Benefits of rhythm training via a tablet serious game in Parkinson's disease
Zhang Acupuncture and Herbal Medicine for Depression from Traditional Empiricism to Research Evidence
Brunoni et al. Mood disorders
Alvarez et al. The effectiveness of relaxation techniques in anxiety disorders
Kanai et al. Effect of the self-monitoring approach on physical activity in hospitalized patients with mild ischemic stroke a randomized controlled trial
Malagola et al. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan
Hong-Bao Effect of clinical pathway on advanced schistosomiasis patients with acites: a report of 220 cases
Vizza Comprehensive lifestyle intervention and group support.
Quintarelli et al. Analysis of Bone Marrow Microenviroment Factors As Early Markers of Response in Patients with Newly Diagnosed Bcr-Abl Positive CML in Chronic Phase Treated with Nilotinib.
Takizawa Message
Huang et al. Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Chronic Steroid-Refractory Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation
JP2015533808A5 (ko)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20774251

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2021556666

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020774251

Country of ref document: EP

Effective date: 20211019